CV risk assessment does not need laboratory tests

Édition française

HeartWire
- News for the CV healthcare professional by theheart.org journalists
- Carotid bruits and CVD
- ACS guideline discrepancies
- FDA expands "extracellular matrix" biomaterial indications
- Natale heads up new arrhythmia institute in Austin
- Largest study on ICDs in kids
- Hormone therapy linked to stroke risk regardless of timing of initiation
- Denervation for CPVT
- Risks of early repolarization
- GI events and clopidogrel
- WAFACS: No benefit to homocysteine lowering
- More...

Editorial series
- A series of discussions among editorial leaders, developed by theheart.org
- HeartBeat
  - Nissen. Califf. Rosiglitazone.
  - More...
- The Cardiology Show
- Cardiology panels
- HeartWire clips
- The EP show
  - Recall Reality
  - More...
- Thumbs up, thumbs down

CME programs

Academic series
- Duke Clinical Medicine Series

Sponsored education
- Promotional educational programs developed under the direction of our sponsors
- Branded infosites
- Condition infosites
  - Atrial Fibrillation infosite
- Promotional educational programs
- Press Center

Forum
- In-depth discussions, moderated by Dr Melissa Walton-Shirley
- Heparin contamination was deliberate act to cut costs?
- Managed-care data suggest high frequency of GI events from clopidogrel
- Vascular benefits of stopping smoking are rapid
- WAFACS published: No CVD benefit in longest-duration folic-acid/B-vitamin supplementation study
- Enoxaparin now affected by heparin contaminant
- More...

The Fellows' corner

Genetic beta-blockade

What are the implications of an exciting discovery of intrinsic genetic beta-blockade common to 40% of people of African ancestry?

Dr Eric Topol invites you to share your opinions.

Click here to view the video blog and join the discussion.

HeartWire clips

On moving to industry: Interview with Dr Terry Ferguson

In conversation with heartwire news and features editor Larry Husten, Dr Terry Ferguson muses on changes to daily life, decision making processes, and patient care from a different perspective resulting from his new position in industry.

The Cardiology Show

Surrogate end points on trial: ENHANCE and other controversies
Part 2 is now live!

Nine of the world's top cardiologists gathered in Chicago to take on the issues raised by data released at the American College of Cardiology Scientific Sessions.

Dr Valentin Fuster moderates this frank and sometimes heated discussion on the results of ENHANCE, STRADIVARIUS, ONTARGET, and PERISCOPE, and the questions they raise about the responsibility of industry and the relevance of surrogate end points.

Forum

Smoking ban?

Read about our forum moderator's heroic and sometimes comic efforts to get a smoking ban passed by her city council in tobacco country.

Thumbs up, thumbs down

Controversies: ENHANCE and ACCORD

Clinical trials are under attack and in the headlines. What is the proper role of the investigators? What are the responsibilities of industry? Join Drs Eric J Topol and Robert M Califf in a discussion of the many issues surrounding ENHANCE and ACCORD.

	Clinical cardiology

CV risk assessment does not need laboratory tests
A risk assessment that substitutes body-mass index for cholesterol levels was just as effective at predicting cardiovascular disease outcomes and could have profound effects on the affordability and availability of an adequate screening program in developing countries, a new study suggests. (Gaziano TA et al. Lancet 2008; 371:923-931.)

To view the full text of this article, you must be logged in as a registered member.